Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

Correction: Mol Cancer 13, 71 (2014)

https://doi.org/10.1186/1476-4598-13-71

Following the publication of the original article [1], the authors would like to update Figure 4 as the SKBR3-LR NC mimic migration image presented in the published article was incorrect, but the associated graph showing % fold change was correct. The error was due to a pasting error when compiling the composite figure (two NC mimic invasion images were inadvertently pasted, instead of one NC mimic migration and one NC mimic invasion image). The incorrect and correct figures are provided below.

Incorrect Figure 4:

Correct Figure 4:

1. Corcoran C, Rani S, Breslin S, et al. miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 2014;13:71. https://doi.org/10.1186/1476-4598-13-71.

   Article CAS PubMed PubMed Central Google Scholar

Download references

Authors and Affiliations

1. School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland

   Claire Corcoran, Sweta Rani, Susan Breslin, Martina Gogarty & Lorraine O’Driscoll

2. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

   Irene M Ghobrial

3. Department of Oncology, St. Vincent’s University Hospital, Dublin 4, Ireland

   John Crown

Authors

1. Claire CorcoranView author publications

   You can also search for this author in PubMed Google Scholar

2. Sweta RaniView author publications

   You can also search for this author in PubMed Google Scholar

3. Susan BreslinView author publications

   You can also search for this author in PubMed Google Scholar

4. Martina GogartyView author publications

   You can also search for this author in PubMed Google Scholar

5. Irene M GhobrialView author publications

   You can also search for this author in PubMed Google Scholar

6. John CrownView author publications

   You can also search for this author in PubMed Google Scholar

7. Lorraine O’DriscollView author publications

   You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lorraine O’Driscoll.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Cite this article

Corcoran, C., Rani, S., Breslin, S. et al. Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer 24, 37 (2025). https://doi.org/10.1186/s12943-025-02251-8

Download citation

• Published: 31 January 2025

• DOI: https://doi.org/10.1186/s12943-025-02251-8

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative